Chronic Lymphocytic Leukemia | Specialty

Dr. Kay on Genetic Investigations in Chronic Lymphocytic Leukemia

August 18th 2016

Neil E. Kay, MD, professor of medicine, Mayo Clinic, discusses the genetic investigations being conducted in chronic lymphocytic leukemia (CLL), and more specifically, monoclonal b-cell lymphocytosis, which resembles CLL but does not meet the same criteria.

Dr. Jeffrey Jones on Long-Term Outcomes With Ibrutinib in CLL

August 16th 2016

Jeffrey Jones, MD, MPH, assistant professor of Internal Medicine, Division of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, discusses the long-term outcomes associated with ibrutinib (Imbruvica) for the treatment of patients with chronic lymphocytic leukemia (CLL).

Dr. Francesco Forconi on Questions That Remain Regarding Inhibiting the B-cell Receptor in CLL

August 12th 2016

Dr. Susan O'Brien Compares Ibrutinib With Chemoimmunotherapy in Frontline CLL

August 11th 2016

Susan M. O'Brien, MD, associate director for Clinical Science for the Chao Family Comprehensive Cancer Center, medical director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research, UC Irvine Health, discusses how ibrutinib (Imbruvica) compares with chemoimmunotherapy as a frontline treatment for patients with chronic lymphocytic leukemia.

Dr. John Byrd on Ibrutinib in CLL

August 9th 2016

Novel Treatment Strategies Emerging for CLL

July 27th 2016

Ibrutinib (Imbruvica) and idelalisib (Zydelig) have become standard of care treatments for patients with relapsed or high-risk chronic lymphocytic leukemia, with ongoing studies in progress to move ibrutinib into the frontline setting.

CAR T-Cell Therapy CTL019 Shows Promise in Phase II CLL Trial

July 22nd 2016

The CD19-targeting CAR T-cell therapy CTL019 induced responses in 53% of patients with relapsed/refractory chronic lymphocytic leukemia, including complete remissions in 35% of patients.

Role of Targeted Therapies Evolving in CLL

July 20th 2016

The treatment landscape for patients with chronic lymphocytic leukemia continues to evolve, as long-term data become available from pivotal studies that led to the FDA approvals for the BTK inhibitor ibrutinib (Imbruvica) and the PI3K inhibitor idelalisib (Zydelig).

Dr. Jennifer Brown on the Role of FCR in CLL

July 13th 2016

Dr. Byrd on Alacabrutinib's Mechanism of Action in CLL

July 8th 2016

John Byrd, MD, director of the Division of Hematology, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, Ohio State University Comprehensive Cancer Center, discusses the mechanism of acalabrutinib, a next-generation BTK inhibitor as a potential treatment for patients with chronic lymphocytic leukemia.

Dr. Francesco Forconi on B-cell Receptor Structure and Function in CLL

July 6th 2016

Francesco Forconi, MD, associate professor of Hematology, University of Southampton, United Kingdom, discusses the role of the B-cell receptor (BCR) in chronic lymphocytic leukemia (CLL).

Preliminary Data for Duvelisib in Indolent NHL

June 29th 2016

PI3K-Targeted Therapy for Follicular Lymphoma

June 29th 2016

Treatment of Follicular Lymphoma

June 29th 2016

Encouraging Early Data for Novel PI3K Inhibitors

June 29th 2016

Duvelisib in Relapsed/Refractory CLL

June 29th 2016

Role of PI3K-Targeted Therapy in CLL

June 29th 2016

Treating Chronic Lymphocytic Leukemia

June 29th 2016

B-Cell Receptor Inhibition Paints a Complex Picture in CLL

June 24th 2016

Francesco Forconi, MD, discusses his research into the B-cell receptor structure and its function in chronic lymphocytic leukemia.

Maintenance Ofatumumab for CLL Unlikely to Receive European Approval

June 24th 2016

The EMA’s Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion to ofatumumab regarding its potential use in the maintenance setting for patients with relapsed chronic lymphocytic leukemia.